FrancophonIA/ELRC3.0 huggingface dataset:
English: The company that markets the medicine will ensure that all doctors expected to prescribe the medicine are provided with an educational pack that includes information on the increased risk of kidney disease with medicines containing tenofovir disoproxil such as this one.
Estonian: Ravimi turustaja varustab kõik ravimit määravad arstid teabepakmega, mis sisaldab teavet neeruhaiguse suurenenud riski kohta tenofoviirdisoproksiili sisaldavate ravimitega nagu
English: Also, it must not be started in patients who have ever been infected with HIV that is resistant to any of the three active substances in the medicine.
Estonian: Ravimit ei tohi kasutada patsiendid, kes on teadaolevalt nakatunud sellise HIV-tüvega, mis on resistentne ravimi mis tahes kolme toimeaine vastu.
English: The full EPAR for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This medicine contains three active substances: efavirenz, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
Estonian: Ravim sisaldab kolme toimeainet: efavirensit, mis on mittenukleosiidne pöördtranskriptaasi inhibiitor (NNRTI), emtritsitabiini, mis on nukleosiidne pöördtranskriptaasi inhibiitor, ja tenofoviirdisoproksiili, mis on tenofoviiri eelravim, mis muundub organismis toimeaineks tenofoviiriks.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is an antiviral medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka on viirusravim, mida kasutatakse inimese immuunpuudulikkuse I tüübi viirusega (HIV1) nakatunud täiskasvanute raviks; HIV1 põhjustab omandatud immuunpuudulikkuse sündroomi (AIDS).
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Atripla, and do not need to be repeated for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Estonian: Võrdlusravimiga Atripla on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Efavirenz/Emtricitabine/Tenofovir disoproxil Krka korrata.
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Estonian: Euroopa avaliku hindamisaruande täistekst võrdlusravimi kohta on Euroopa Ravimiameti veebilehel.
English: The medicine contains the active substances efavirenz, emtricitabine and tenofovir disoproxil and is a ‘generic medicine'.
Estonian: Ravim sisaldab toimeainena efavirensi, emtritsitabiini ja tenofoviirdisoproksiili ning see on geneeriline ravim.
English: Because Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Efavirenz/Emtricitabine/Tenofovir disoproxil Krka on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samaks mis võrdlusravimil.
English: What is Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and what is it used for?
Estonian: Mis on Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ja milleks seda kasutatakse?
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka keeps the amount of HIV in the blood at a low level.
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka hoiab HIV-sisalduse veres väikese.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka efavirenz / emtricitabine / tenofovir disoproxil
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka efavirens/emtritsitabiin/tenofoviirdisoproksiil
English: For practical information about using Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The European Medicines Agency concluded that, in accordance with EU requirements, the medicine has been shown to have comparable quality and to be bioequivalent to Atripla.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka võrreldav kvaliteet ja bioekvivalentsus ravimiga Atripla.
English: Other information about Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Estonian: Muu teave ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kohta
English: Recommendations and precautions to be followed by healthcare professionals and patients for its safe and effective use have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Both nucleoside and nucleotide reverse transcriptase inhibitors are commonly known as NRTIs.
Estonian: Nukleosiidsete ja nukleotiidsete pöördtranskriptaasi inhibiitorite ühine lühend on NRTI.
English: For more information about treatment with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Efavirenz/Emtricitabine/Tenofovir disoproxil Krka toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: All three active substances block the activity of reverse transcriptase, an enzyme that allows HIV to reproduce itself in the cells it has infected.
Estonian: Pöördtranskriptaas on ensüüm, mis võimaldab HI-viirusel nakatunud rakkudes paljuneda.
English: This means that it contains the same active substances and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Atripla.
Estonian: See tähendab, et Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sisaldab samu toimeaineid ja toimib samal viisil kui võrdlusravim Atripla, millel juba on Euroopa Liidus müügiluba.
English: This is a summary of the European public assessment report (EPAR) for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Estonian: See on ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Euroopa avaliku hindamisaruande kokkuvõte.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka on 8 February 2018.
Estonian: Ravimiamet soovitas ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kasutamise Euroopa Liidus heaks kiita.
English: Therefore, the Agency's view was that, as for Atripla, the benefit outweighs the identified risk.
Estonian: Seetõttu on ravimiamet arvamusel, et nagu ka Atripla korral, ületab ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kasulikkus sellega kaasnevad riskid.
English: It can be used in the following ways:
Estonian: Seda tohib kasutada järgmiselt:
English: This summary was last updated in 11-2012.
Estonian: Kokkuvõtte viimane uuendus: 11-2012.
English: Some of the patients were also taking metformin.
Estonian: Teatud patsiendid said ka metformiini.
English: The daily dose should not exceed two tablets (100 mg).
Estonian: Ööpäevane annus ei tohi ületada kaht tabletti (100 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xiliarx on 19 November 2008.
Estonian: Euroopa Komisjon andis Xiliarxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. novembril
English: The full EPAR for Xiliarx can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Xiliarxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (50 mg).
Estonian: Seda turustatakse tablettidena (50 mg).
English: Xiliarx vildagliptin
Estonian: Xiliarx vildagliptiin
English: Together, these processes reduce blood glucose levels and help to control type 2 diabetes.
Estonian: Need protsessid koos vähendavad vere glükoosisisaldust ja aitavad II tüüpi diabeeti reguleerida.
English: However, in another study involving 449 patients taking insulin, the size of this effect was significant.
Estonian: Teises uuringus, kus osales 449 insuliini saavat patsienti, oli mõju märkimisväärne.
English: • one tablet in the morning (50 mg per day) when taken with a sulphonylurea.
Estonian: • üks tablett hommikul (50 mg ööpäevas) kasutamisel koos sulfonüüluurearavimiga.
English: This is a summary of the European public assessment report (EPAR) for Xiliarx.
Estonian: See on ravimi Xiliarx Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xiliarx.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Xiliarx is a medicine that contains the active substance vildagliptin.
Estonian: Xiliarx on ravim, mis sisaldab toimeainena vildagliptiini.
English: For more information about treatment with Xiliarx, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Xiliarxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The most common side effect with Xiliarx (seen in between 1 and 10 patients in 100) is dizziness.
Estonian: Xiliarxi kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on peapööritus.
English: Because vildagliptin has been associated with liver problems, patients should have tests to check their liver function before treatment with Xiliarx and at regular intervals during treatment.
Estonian: Et vildagliptiini on seostatud maksaprobleemidega, tuleb kontrollida patsientide maksatalitlust enne Xiliarxiga ravi alustamist, samuti regulaarsete ajavahemike järel ravi ajal.
English: Xiliarx should therefore be used only in patients for whom metformin is inappropriate either because of side effects occurring with metformin or because they have a condition that makes metformin unsuitable for them.
Estonian: Xiliarxi tohib seetõttu kasutada ainult patsientidel, kellele metformiin ei sobi kas metformiini kõrvalnähtude tõttu või selle tõttu, et neil on terviseseisund, mille korral ei saa metformiini kasutada.
English: Other information about Xiliarx
Estonian: Muu teave Xiliarxi kohta
English: Xiliarx has been studied in eleven main studies involving a total of over 5,000 patients with type 2 diabetes and insufficient control of blood glucose levels.
Estonian: Xiliarxi uuriti 11 põhiuuringus, milles osales kokku üle 5000 II tüüpi diabeediga patsiendi, kelle organism ei suutnud glükoosisisaldust veres piisavalt reguleerida.
English: Xiliarx must not be used in people who are hypersensitive (allergic) to vildagliptin or any of the other ingredients.
Estonian: Xiliarxi ei tohi kasutada patsiendid, kes on vildagliptiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: These hormones are released after a meal and stimulate the pancreas to produce insulin.
Estonian: Need hormoonid vabanevad pärast söömist ja stimuleerivad insuliini teket kõhunäärmes.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse (nn veresuhkru) reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: For the full list of all side effects reported with Xiliarx, see the package leaflet.
Estonian: Xiliarxi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In all studies, the main measure of effectiveness was the change in blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
Estonian: Kõigis uuringuis oli efektiivsuse põhinäitaja glükohemoglobiini (HbA1c) sisalduse muutus veres, mis näitab vere glükoosisisalduse reguleeritust.
English: In the study involving 296 patients taking insulin, adding Galvus caused a greater reduction in HbA1c levels than adding placebo, but the size of this effect was small possibly due to the fact that the study included long-term patients who were less likely to show improvement..
Estonian: Uuringus, kus osales 296 patsienti, kes said insuliini, vähenes Galvuse lisamisel HbA1c sisaldus rohkem kui platseebo lisamisel, kuid toime oli vähene, sest uuring hõlmas pikaajalisi patsiente, kelle seisundi paranemise tõenäosus oli väiksem.
English: • one tablet in the morning and another in the evening (100 mg per day), when used alone, with metformin, with a thiazolidinedione, with metformin plus a sulphonylurea, or with insulin (with or without metformin);
Estonian: • üks tablett hommikul ja teine õhtul (100 mg ööpäevas) kasutamisel ainsa ravimina, koos metformiini või tiasolidiindioonravimiga, koos metformiini ja sulfonüüluurearavimiga või koos insuliiniga (koos metformiiniga või ilma);
English: A lower dose of the sulphonylurea may also be considered to reduce the risk of hypoglycaemia (low blood glucose levels).
Estonian: Sulfonüüluurearavimi väiksem annus võib vähendada ka hüpoglükeemia (tavalisest väiksem glükoosisisaldus veres) riski.
English: The CHMP noted that Xiliarx was effective as an add-on to metformin, a thiazolidinedione, or a sulphonylurea (dual therapy), a sulphonylurea and metformin (triple therapy) or insulin with or without metformin, and concluded that the benefits of the add-on treatment outweigh the risks.
Estonian: Inimravimite komitee märkis, et Xiliarx oli lisamisel metformiini, tiasolidiindioon- või sulfonüüluurearavimiga toimuvale ravile (ravi kahe preparaadiga), sulfonüüluurearavimi ja metformiiniga toimuvale ravile (ravi kolme preparaadiga) või insuliinile (metformiiniga või ilma) efektiivne, ja järeldas, et lisaravi kasulikkus ületab kaasnevaid riske.
English: Four studies compared the effects of Xiliarx, taken at doses of 50 or 100 mg a day for 24 weeks, with those of placebo, when used as an add-on to existing treatment with metformin (544 patients), pioglitazone (a thiazolidinedione, 463 patients), glimepiride (a sulphonylurea, 515 patients) or insulin (296 patients).
Estonian: 4 uuringus võrreldi Xiliarxi toimet (annuses 50 või 100 mg ööpäevas 24 nädala jooksul) platseebo toimega, kui seda lisati senisele ravile metformiini (544 patsienti), pioglitasooni (teatud tiasolidiindioonravim, 463 patsienti), glimepiriidi (teatud sulfonüüluurearavim, 515 patsienti) või insuliiniga (296 patsienti).
English: What is Xiliarx?
Estonian: Mis on Xiliarx?
English: Xiliarx is used to treat type 2 diabetes mellitus.
Estonian: Xiliarxi kasutatakse II tüüpi diabeedi (suhkurtõve) ravimiseks.
English: Vildagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
Estonian: Vildagliptiin vähendab ka maksas tekkiva glükoosi kogust, suurendades insuliini ja vähendades glükagooni (teatud hormoon) sisaldust.
English: Vildagliptin does not work when the blood glucose is low.
Estonian: Kui vere glükoosisisaldus on väike, vildagliptiin ei toimi.
English: A further study compared Galvus with placebo as an add-on treatment in 318 patients who were already taking metformin and glimepiride.
Estonian: Täiendavas uuringus võrreldi Galvust platseeboga lisaravimina 318 patsiendi, kes juba said metformiini ja glimepiriidi.
English: In the study comparing Xiliarx with metformin, significantly better results were seen with metformin: a reduction in HbA1c of 1.5 percentage points after 52 weeks compared with a reduction of around 1 percentage point in patients treated with Xiliarx.
Estonian: Uuringus, kus Xiliarxi võrreldi metformiiniga, saavutati metformiiniga oluliselt paremad tulemused: HbA1c sisaldus vähenes 52 nädala järel metformiini rühmas 1,5% võrra ja Xiliarxi rühmas ligikaudu 1% võrra.
English: Why has Xiliarx been approved?
Estonian: Miks Xiliarx heaks kiideti?
English: • together with metformin, a thiazolidinedione or a sulphonylurea (dual therapy) when the patient's diabetes is insufficiently controlled by this other medicine taken alone, but it is only used in combination with a sulphonylurea in patients who cannot take metformin;
Estonian: • koos metformiini või tiasolidiindioon- või sulfonüüluurearavimiga (ravi kahe preparaadiga), kui ainult selle muu ravimi kasutamisel diabeet ravile ei allu; koos sulfonüüluurearavimiga kasutatakse seda ainult patsientidel, kes ei saa metformiini kasutada;
English: What is the risk associated with Xiliarx?
Estonian: Mis riskid Xiliarxiga kaasnevad?
English: Five of these studies looked at the effects of Xiliarx taken alone in a total of 3,644 patients, comparing it with placebo (a dummy treatment), metformin, rosiglitazone (a thiazolidinedione) or gliclazide (a sulphonylurea).
Estonian: Neist 5 uuringus vaadeldi Xiliarxi toimet kasutamisel ainsa ravimina kokku 3644 patsiendil, võrreldes seda platseebo (näiv ravim), metformiini, rosiglitasooni (teatud tiasolidiindioonravim) või gliklasiidiga (teatud sulfonüüluurearavim).
English: A further study compared Galvus with placebo as an add-on treatment in 449 patients who were already taking a stable dose of long-acting insulin.
Estonian: Täiendavas uuringus võrreldi Galvust platseeboga lisaravimina 449 patsiendi, kes juba said püsiva annuse pika toimeajaga insuliini.
English: By increasing levels of incretin hormones in the blood, vildagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Estonian: Kui vere glükoosisisaldus on suur, stimuleerib vildagliptiin kõhunääret tekitama rohkem insuliini, suurendades inkretiinhormoonide sisaldust veres.
English: Xiliarx used on its own was effective at reducing levels of HbA1c, but was less effective than the comparator medicines.
Estonian: Ainsa ravimina kasutamisel vähendas Xiliarx HbA1c sisaldust, kuid oli vähem efektiivne kui ravimid, millega seda võrreldi.
English: Patients taking Galvus in addition to insulin, with or without metformin, had a reduction in HbA1c levels of 0.77 percentage points, compared with 0.05 percentage points in patients taking placebo in addition to insulin.
Estonian: Patsientidel, kes võtsid lisaks insuliinile Galvust koos metformiiniga või ilma, vähenes HbA1c sisaldus veres 0,77%, lisaks insuliinile platseebot saanud patsientidel 0,05%.
English: In contrast, patients adding placebo to their existing treatment showed smaller changes in HbA1c levels, ranging from a fall of 0.3 to a rise of 0.2 percentage points.
Estonian: Seevastu patsientidel, kelle senisele ravile lisati platseebot, muutus HbA1c sisaldus veres vähem: langusest 0,3% võrra kuni tõusuni 0,2% võrra.
English: The active substance in Xiliarx, vildagliptin, is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
Estonian: Xiliarxis toimeainena sisalduv vildagliptiin on ensüümi dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mille toime seisneb inkretiinhormoonide organismis lagunemise blokeerimises.
English: In combination with glimepiride, both 50 mg and 100 mg daily doses caused a reduction of around 0.6 percentage points.
Estonian: Kasutamisel koos glimepiriidiga vähendasid mõlemad annused, 50 mg ja 100 mg ööpäevas, HbA1c sisaldust ligikaudu 0,6% võrra.
English: When used as an add-on to existing treatment for type 2 diabetes, Xiliarx was more effective than placebo in reducing HbA1c levels.
Estonian: Lisamisel II tüüpi diabeedi olemasolevale ravimile vähendas Xiliarx HbA1c sisaldust platseebost efektiivsemalt.
English: • together with insulin (with or without metformin) in patients whose diabetes is not sufficiently controlled by diet and exercise plus a stable dose of insulin.
Estonian: • koos insuliiniga (koos metformiiniga või ilma) patsientidel, kelle diabeeti ei saa rahuldavalt reguleerida dieedi, kehalise koormuse ja insuliini püsiva annusega.
English: In adults, the recommended dose of Xiliarx is:
Estonian: Xiliarxi soovitatav annus täiskasvanutel:
English: The CHMP also considered the use of Xiliarx on its own and concluded that it was effective in reducing blood glucose but less so than metformin.
Estonian: Inimravimite komitee arutas ka Xiliarxi kasutamist ainsa ravimina ja järeldas, et see oli HbA1c sisalduse vähendamisel efektiivne, kuid vähem kui metformiin.
English: • together with a sulphonylurea and metformin (triple therapy) in patients whose diabetes is not sufficiently controlled by these medicines plus diet and exercise;
Estonian: • koos sulfonüüluurearavimi ja metformiiniga (ravi kolme preparaadiga) patsientidel, kelle diabeeti ei saa rahuldavalt reguleerida nende ravimite ning dieedi ja kehalise koormusega;
English: With metformin and with pioglitazone, the 100 mg daily dose was more effective than the 50 mg daily dose, with a reduction in HbA1c levels of between 0.8 and 1.0 percentage points.
Estonian: Kasutamisel koos metformiini ja pioglitasooniga oli 100 mg ööpäevane annus efektiivsem kui 50 mg annus: HbA1c sisaldus vähenes 0,8-1% võrra.
English: In combination with metformin and glimepiride, 50 mg Galvus taken twice a day reduced HbA1c levels by 1 percentage point, compared with a reduction of 0.3 percentage points in patients taking placebo.
Estonian: Kasutamisel koos metformiini ja glimepiriidiga vähendas Galvuse 50 mg annus kaks korda ööpäevas HbA1c sisaldust veres 1% võrra, samas kui platseebot kasutanud patsientidel oli see näitaja 0,3%.
English: • on its own (monotherapy) in patients whose diabetes is not sufficiently controlled by diet and exercise and who cannot take metformin;
Estonian: • ainsa ravimina patsientidel, kelle diabeeti ei saa rahuldavalt reguleerida dieedi ja kehalise koormusega ning kes ei saa kasutada metformiini;
English: What benefit has Xiliarx shown during the studies?
Estonian: Milles seisneb uuringute põhjal Xiliarxi kasulikkus?
English: What is Xiliarx used for?
Estonian: Milleks Xiliarxi kasutatakse?
English: How has Xiliarx been studied?
Estonian: Kuidas Xiliarxi uuriti?
English: How is Xiliarx used?
Estonian: Kuidas Xiliarxi kasutatakse?
English: How does Xiliarx work?
Estonian: Kuidas Xiliarx toimib?
English: The physician information should contain the following key messages:
Estonian: Arsti teave peab sisaldama järgmisi olulisi sõnumeid:
English: • The need to evaluate patients for both active and inactive tuberculosis prior to starting the treatment, including use of appropriate screening tests,
Estonian: • vajadus hinnata patsiente nii aktiivse kui ka mitteaktiivse tuberkuloosi suhtes enne ravi algust, sealhulgas sobivate sõeltestide kasutamine;
English: • Physician information
Estonian: • arsti teave,
English: • The role and use of patient alert card.
Estonian: • patsiendi häirekaardi osa ja kasutamine.